Keywords
Botulinum toxins type A
Muscle spasticity
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To describe the clinical and epidemiological profile of patients with spastic cerebral palsy treated by the pediatric orthopedics service at a referral hospital in Northern Brazil. Methods: This is an observational, retrospective, cross-sectional, descriptive, and analytical study, in which patient records were analyzed to explore the association between the epidemiological profile and cases of cerebral palsy. Results: A total of 103 patients diagnosed with spastic cerebral palsy were included, the majority of whom were male (60.2%), with a mean age of approximately 9 years. About 32% of the patients can communicate verbally, but with difficulty, and 38.8% are unable to walk and require the exclusive use of a wheelchair. Most of the mothers had adequate prenatal care (64.1%); however, most of the children were born preterm (57.3%), which explains the main complications associated with CP in this study: prematurity, hypoxia, and fetal anoxia. A total of 83.5% of the patients use Botulinum Toxin type A (BTA), with the lower limbs being the most affected. Conclusion: At the end of the study, it was concluded that care begins before the gestational period and extends to specific post-diagnosis care. When initiated early, deficits are mitigated.
References
ASHWORTH B. Preliminary trial of carisoprodol in multiple sclerosis. The Practitioner, 1964; 192: 540-542.
BJORNSON K, et al. Toxina botulínica para espasticidade em crianças com paralisia cerebral: uma avaliação abrangente. Pediatrics. 2007; 120(1): 49–58.
BOYD RN e GRAHAM HK. Medição objetiva de achados clínicos no uso de toxina botulínica tipo A para o tratamento de crianças com paralisia cerebral. Eur J Neurol, 1999; 6: 23-35.
CAMARGO LG e ABREU IS. Oral health of children with cerebral palsy: assessment of the knowledge of their parents or caregivers. Revista de Pesquisa Cuidado É Fundamental Online, 2022; 14: 1-6.
CARVALHO IJ, et al. Enfrentamento da incerteza na doença pelo cuidador informal de crianças com paralisia cerebral. Revista da Escola de Enfermagem da Usp, 2023; 57.
COSTA WM e NASCIMENTO GK. Análise da mastigação e deglutição na paralisia cerebral com deficiência visual: estudo de caso. Distúrbios da Comunicação, 2021; 33(2): 204-212.
DANTAS EM, et al. O uso da estimulação transcraniana como tratamento na reabilitação motora de criança com paralisia cerebral - projeto de estudo de caso. Revista Ciencias de La Actividad Física, 2022; 23: 1-9.
DANTAS MS, et al. Vivências singulares de profissionais de saúde na rede e apoio social à criança com paralisia cerebral. Cogitare enferm, 2019; 24.
DEEKSH A, et al. Pregnancy in Women With Cerebral Palsy. Cureus, 2023.
ELHOSSINY F. Ultrasound-guided botulinum toxin injections of salivary glands in cerebral palsy children with sialorrhea. Bioactive compounds in health and disease, 2024.
KRIGGER KW. Paralisia cerebral: uma visão geral. Am Fam Physician, 2006; 73(1): 91–100.
LYNN BO, et al. A relação entre as propriedades de alongamento do gastrocnêmio medial e os reflexos de alongamento na paralisia cerebral. Frontiers in Pediatrics, 2018.
MAEDA K. Prevention and treatment of cerebral palsy caused by intrapartum damage with novel hypoxia index. Journal of Stem Cell Research & Therapeutics, 2018.
MAGALHÃES PH, et al. Parâmetros lineares da marcha de crianças com paralisia cerebral do tipo espástica: estudo de caso. Revista Pesquisa em Fisioterapia, 2020; 10(3): 529-536.
MARVULLI R, et al. Intrathecal Baclofen Infusion-Botulinum Toxin Combined Treatment Efficacy in the Management of Spasticity due to Cerebral Palsy. Cns & Neurological Disorders-drug Targets, 2024.
NEDA R, et al. Pre-pregnancy and pregnancy disorders, pre-term birth and the risk of cerebral palsy: a population-based study. International Journal of Epidemiology, 2023.
PALISANO RJ, et al. Development and validation of a Gross Motor Function Classification System for children with cerebral palsy. Developmental Medicine & Child Neurology, 1997; 39(4): 214-223.
PEREZ-POLO R. Hypoxia ischemia update. International Journal of Developmental Neuroscience, 2018.
PFEIFER LI, et al. Classification of cerebral palsy: association between gender, age, motor type, topography and Gross Motor Function. Arq Neuropsiquiatr., 2009; 67(4): 1057-61.
ROSENBAU M, et al. Classification in Childhood Disability. J Child Neurol, 2014; 29(8): 1036-45.
SANTOS KH, et al. O trabalho de profissionais na residência multiprofissional em saúde. Rev. Aps, 2016; 19(3): 495-499.
SEVERIANO JE, et al. Efeitos do uso de vestes terapêuticas em programas de reabilitação de crianças com paralisia cerebral: uma revisão integrativa da literatura. Revista Brasileira de Ciência e Movimento, 2022; 30(1): 18.
SHANNON M, et al. Antenatal Antecedents and the Impact of Obstetric Care in the Etiology of Cerebral Palsy. Clinical Obstetrics and Gynecology, 2008.
SRINIVASA R, et al. Cerebral palsy: antenatal risk factors. Journal of Evolution of medical and Dental Sciences, 2015.
STAM LP. Advantages of spasticity treatment with botulinum toxin A in combination with controlled dynamic stretching orthoses for the treatment of contractures compared to botulinum toxin A as the only therapy. Clinical Neurophysiology, 2022.
SUSAN R. The use of botulinum toxin therapy for lower-extremity spasticity in children with cerebral palsy. Neurosurgical Focus, 2006.
THE JAMOVI PROJECT. Jamovi (Versão 2.3.28). [Software Computacional]. Disponível em: https ://www.jamovi.org.
ZARDO F, et al. Análise da ativação muscular em indivíduos com paralisia cerebral através de manuseios do conceito bobath: uma revisão crítica. Revista Brasileira de Ciência e Movimento, 2020; 1: 29.